查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016906

結核病診斷市場：全球市場按產品類型、技術、檢測類型、最終用戶和應用分類的預測，2026-2032年

Tuberculosis Diagnostics Market by Product, Technology, Test Type, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，結核病診斷市場價值將達到 24.5 億美元，到 2026 年將成長至 25.9 億美元，到 2032 年將達到 38.8 億美元，複合年成長率為 6.77%。

主要市場統計數據
基準年 2025 24.5億美元
預計年份：2026年 25.9億美元
預測年份 2032 38.8億美元
複合年成長率 (%) 6.77%

引言概述了影響整個醫療保健系統中結核病診斷和決策的現代臨床、實驗室和政策促進因素。

結核病仍然是一項重大的公共衛生挑戰，需要臨床、實驗室和公共衛生系統之間協調一致的診斷應對措施。目前的診斷涉及多種技術、檢體處理流程和終端用戶，每一項都會影響臨床決策和病患預後。隨著診斷工具的不斷發展，從臨床醫生到實驗室的相關人員必須適應不斷變化的法規環境、供應鏈趨勢和疾病流行病學的變化。因此，對當前趨勢及其戰略意義的簡明總結有助於更明智地分配資源和技術選擇。

分子技術的快速發展、數位影像技術的進步以及系統互通性的提高，是如何在現實世界中改變結核病診斷和臨床路徑的？

結核病診斷格局正經歷一系列變革，其驅動力包括技術創新、臨床重點的轉變以及操作流程的現代化。分子技術，特別是快速核酸增幅檢查和基因分型，正從專業實驗室向更分散的應用領域轉移，從而縮短檢測時間並實現更早的治療決策。同時，非分子方法，例如人工智慧驅動的數位放射線和改進的免疫學檢測，也在不斷完善病例發現和分診策略，從而構建出更多層次的診斷路徑，以平衡敏感性、特異性和資源限制。

評估美國於 2025 年對診斷設備採購、供應鏈韌性和供應商策略徵收的關稅對營運和採購的累積影響。

計劃於2025年實施的關稅徵收和貿易政策調整正在影響診斷價值鏈中的籌資策略、供應商選擇和零件採購。關稅壓力往往會增加進口設備和耗材的到貨成本，促使檢查室管理人員和採購負責人重新審視供應商合約並探索替代籌資策略。為此，許多相關人員正在考慮利用區域供應商、簽訂長期供應商合約以及增加庫存緩衝，以降低成本波動和運輸延誤的風險。

將產品類型、技術分類、測試目的、最終用戶環境和臨床應用與採購和營運策略連結起來的詳細細分分析。

了解市場細分對於使產品策略與臨床效用和採購週期相匹配至關重要。從產品細分來看，市場涵蓋耗材和儀器，其中耗材包括試劑盒和試劑。這些耗材需要重複採購，因此需要持續的採購決策和低溫運輸物流。而儀器則需要資本規劃、安裝和維護，因此採購選擇通常反映了長期的臨床工作流程和服務合約。這些產品層面的差異也會影響供應商合約、保固結構和培訓計畫。

美洲、歐洲、中東和非洲以及亞太地區在診斷取得、部署優先事項和能力建構挑戰的區域比較。

區域趨勢影響著不同地區診斷技術的可近性、實施模式和優先事項。在美洲，許多都市區完善的檢查室基礎設施使得分子診斷能夠快速實施並與電子健康記錄整合。同時，即時檢測技術和行動篩檢計畫在支援服務不足地區和農村社區方面發揮重要作用。此外，結核病與合併症以及弱勢群體之間的關聯正日益成為一項重要的計畫重點，並影響檢體體轉診網路和臨床醫師培訓計畫。

企業層面的趨勢著重於策略夥伴關係、技術專長和營運能力，以推動診斷方法的採用和永續性。

老牌跨國診斷試劑製造商與專業創新者的共存正在推動技術進步和市場動態。分子診斷平台製造商優先考慮擴展檢測參數、提高處理能力和增強連接性，以滿足不同檢查室環境的需求。同時，專注於耗材和試劑的公司則強調品管、批間一致性和可靠的物流，以支持檢測項目的順利進行。此外，致力於開發針對抗藥性標記物的標靶檢測方法和快速藥敏分析的專業公司數量也顯著增加，以滿足臨床上對更快指南治療的需求。

為領導企業提供切實可行的策略挑戰，以加強夥伴關係產品組合、供應鏈、人才能力、數據整合和相關人員。

產業領導企業應採取多管齊下的策略，平衡創新、業務永續營運和相關人員參與。首先，他們應優先考慮模組化技術組合，以便快速適應不斷變化的臨床需求，而無需對平台進行全面改造。這種方法降低了技術過時的風險，並使檢查室能夠根據臨床需求的變化擴展特定檢測項目。其次，他們應透過與多家供應商簽訂正式合約、制定區域庫存策略和服務水準承諾，提高供應鏈透明度，並降低貿易中斷和零件短缺的風險。

採用透明的多來源調查方法，整合相關人員訪談、臨床證據、監管指南和供應鏈評估，以檢驗研究結果。

本文所呈現的綜合研究是基於結構化且透明的調查方法，整合了多種證據來源，以建構可靠的研究結論。關鍵資料來源包括對實驗室主任、臨床醫生、採購負責人和製造商負責人相關人員的訪談，這些訪談提供了關於營運挑戰和推廣應用促進因素的第一手觀點。此外，本文還系統性回顧了同行評審的臨床文獻、權威公共衛生機構的技術指南以及監管部門的批准核准，從而對該技術的性能和預期用途進行了背景分析。

簡明結論強調，技術進步、營運韌性和協調實施正在融合，以改善結核病診斷的結果。

總之，結核病診斷正處於轉折點，由於技術進步、區域應用趨勢和供應鏈因素的相互作用，診斷路徑正在重新定義。分子技術和非分子技術相互補充，從而能夠採用多層次的方法進行檢測、分流和抗藥性分析。這些方法若能與醫療保健系統有效整合，可以改善臨床療效。同時，籌資策略和營運實踐必須適應地緣政治趨勢和不斷變化的需求模式，以確保及時獲得必要的診斷工具。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 結核病診斷市場：依產品分類

  • 消耗品
    • 成套工具
    • 試劑
  • 裝置

第9章 結核病診斷市場：依技術分類

  • 分子
    • 基因分型
    • 核酸增幅檢查
  • 非分子
    • 診斷影像
    • 免疫學檢測

第10章 結核病診斷市場：依檢測類型分類

  • 檢測測試
    • 驗血
    • 培養試驗
    • 分子檢測
    • 皮膚反應測試
    • 塗片顯微鏡檢查
  • 藥物敏感性試驗
    • 分子藥物敏感性試驗
    • 表現型藥物敏感性試驗

第11章 結核病診斷市場：依最終用戶分類

  • 診所
  • 醫院
  • 測試機構

第12章 結核病診斷市場：依應用分類

  • 活動性肺結核
    • 肺外結核病
    • 肺結核
  • 潛伏性結核病

第13章 結核病診斷市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 結核病診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 結核病診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國結核病診斷市場

第17章：中國結核病診斷市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Molecular Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Cepheid, Inc.
  • Hain Lifescience GmbH
  • Hologic, Inc.
  • Molbio Diagnostics Private Limited
  • Oxford Immunotec
  • QIAGEN NV
  • Roche Diagnostics International AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-03252A5F9274

The Tuberculosis Diagnostics Market was valued at USD 2.45 billion in 2025 and is projected to grow to USD 2.59 billion in 2026, with a CAGR of 6.77%, reaching USD 3.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.45 billion
Estimated Year [2026] USD 2.59 billion
Forecast Year [2032] USD 3.88 billion
CAGR (%) 6.77%

A focused introduction that frames contemporary clinical, laboratory, and policy drivers shaping tuberculosis diagnostics and decision-making across healthcare systems

Tuberculosis remains a critical public health challenge that demands a coordinated diagnostic response across clinical, laboratory, and public health systems. The diagnostic landscape encompasses a broad array of technologies, specimen workflows, and end users, each of which influences clinical decision-making and patient outcomes. As diagnostic tools evolve, stakeholders from clinicians to reference laboratories must navigate changing regulatory environments, supply chain dynamics, and shifting disease epidemiology. Consequently, a concise synthesis of current trends and strategic implications supports more informed resource allocation and technology adoption choices.

This executive summary synthesizes cross-cutting themes that shape diagnostic practice and procurement, emphasizing technological advances, operational bottlenecks, and policy drivers. It also highlights segmentation-specific considerations that affect procurement cycles and clinical utility, spanning consumables through instruments and molecular through nonmolecular platforms. By framing these insights within contemporary clinical priorities, the narrative informs leaders who are responsible for deploying diagnostics at scale and integrating them into broader care pathways. Moving from descriptive context to strategic implications, the summary outlines how organizations can align investments with evolving diagnostic needs while maintaining patient-centered outcomes and system resilience.

How rapid molecular innovation, digital imaging advances, and system interoperability are reshaping tuberculosis diagnostics and clinical pathways in practice

The diagnostic landscape for tuberculosis is undergoing a series of transformative shifts driven by technological innovation, evolving clinical priorities, and operational modernization. Molecular techniques, particularly rapid nucleic acid amplification tests and genotypic assays, have moved from specialized reference settings toward more decentralized use, reducing time-to-result and enabling earlier therapeutic decisions. At the same time, nonmolecular modalities such as digital radiography augmented with artificial intelligence and improved immunological assays continue to refine case-finding and triage strategies, enabling a more layered diagnostic pathway that balances sensitivity, specificity, and resource constraints.

Concurrently, integration trends are changing how diagnostics are delivered within health systems. Laboratories increasingly emphasize interoperability with electronic medical records and laboratory information systems, while point-of-care deployments prioritize ease of use and connectivity for remote monitoring. These shifts are complemented by policy and programmatic changes that prioritize rapid detection of drug-resistant strains, improve linkage-to-care, and support active case finding in high-burden populations. As a result, healthcare providers and procurement teams face new decisions about technology mix, training needs, and long-term operational sustainability, prompting a re-evaluation of investment priorities and implementation roadmaps.

Assessing the cumulative operational and procurement ramifications of United States tariffs introduced in 2025 on diagnostics sourcing, supply chain resilience, and vendor strategies

The introduction of tariffs and trade policy adjustments in 2025 has influenced procurement strategies, supplier selection, and component sourcing within the diagnostics value chain. Tariff pressures tend to increase landed costs for imported instruments and consumables, prompting laboratory managers and procurement officers to reassess vendor contracts and consider alternative sourcing strategies. In response, many stakeholders have explored regional suppliers, long-term supplier agreements, and increased inventory buffers to mitigate the risk of cost volatility and shipment delays.

Moreover, tariffs can accelerate supplier diversification and local manufacturing initiatives as manufacturers seek to minimize exposure to trade barriers. This shift may alter supply networks over time and encourage investment in manufacturing capabilities closer to demand centers. Simultaneously, regulatory authorities and purchasers have placed greater emphasis on supply chain transparency, contract flexibility, and contingency planning to maintain continuity of diagnostic services. Collectively, these developments underscore the need for procurement teams and corporate strategists to incorporate trade policy scenarios into operational planning while preserving clinical performance and timely access to diagnostic tools.

Detailed segmentation analysis linking product types, technology classes, test purposes, end-user settings, and clinical applications to procurement and operational strategies

Understanding segmentation is essential for aligning product strategy with clinical utility and procurement cycles. Based on product, the market spans consumables and instruments, with consumables comprising kits and reagents whose recurring nature drives ongoing purchasing decisions and cold-chain logistics. Instruments require capital planning, installation, and maintenance programs, and therefore procurement choices often reflect longer-term clinical workflows and service agreements. This product-level differentiation also influences supplier contracts, warranty structures, and training commitments.

Based on technology, the landscape divides into molecular and nonmolecular approaches. Molecular technologies include genotypic assays and nucleic acid amplification tests that excel in rapid detection and resistance profiling, while nonmolecular approaches encompass imaging modalities and immunological assays that support screening, triage, and latent infection assessment. Each technology pathway has distinct operational characteristics relating to sample handling, throughput, and laboratory biosafety requirements. Based on test type, diagnostics are categorized into detection tests and drug susceptibility testing. Detection tests include blood tests, culture-based tests, molecular tests, skin tests, and smear microscopy; they guide initial diagnosis and case identification. Drug susceptibility testing is further distinguished into molecular DST and phenotypic DST, both of which are critical for informing effective treatment regimens and public health containment strategies.

Based on end user, deployment considerations vary across clinics, hospitals, and reference laboratories. Clinics often prioritize ease of use and rapid turnaround to support point-of-care decisions, hospitals balance throughput and comprehensive reporting for inpatient care, and reference laboratories handle complex assays and confirmatory testing. Based on application, the diagnostic pathway differentiates between active tuberculosis and latent tuberculosis, where active disease further segments into extrapulmonary and pulmonary presentations; these clinical distinctions dictate specimen types, diagnostic algorithms, and downstream clinical management. Taken together, these segmentation lenses inform procurement priorities, capacity planning, and clinical integration strategies that stakeholders must reconcile when designing diagnostic networks.

Comparative regional perspectives on diagnostic access, implementation priorities, and capacity-building imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape diagnostic availability, adoption patterns, and implementation priorities across geographies. In the Americas, strong laboratory infrastructure in many urban centers enables adoption of rapid molecular diagnostics and integration with electronic health records, while outreach to underserved and rural communities emphasizes point-of-care technologies and mobile screening initiatives. Meanwhile, programmatic priorities increasingly address the intersection of tuberculosis with comorbidities and vulnerable populations, which influences specimen referral networks and clinician training programs.

In Europe, Middle East & Africa, heterogeneous health system capacity drives a mixed-pace adoption pattern where advanced centralized laboratories coexist with resource-constrained peripheral sites. This region places high importance on capacity-building, procurement collaborations, and regulatory alignment to ensure quality and consistency across borders. Investments in decentralization are balanced against the need to maintain quality assurance and confirmatory testing pathways. In the Asia-Pacific, high-burden settings have catalyzed rapid uptake of point-of-care molecular diagnostics, strengthened laboratory networks, and prioritized strategies for drug-resistant tuberculosis. Regional manufacturers and public-private partnerships play a significant role in scaling access, while digital health initiatives and community-based screening programs complement diagnostic investments. Across regions, cross-cutting themes such as supply chain resilience, workforce development, and the harmonization of diagnostic algorithms remain central to successful implementation.

Company-level dynamics highlighting strategic partnerships, technological specialization, and the operational capabilities that drive diagnostic adoption and sustainability

A mix of established multinational diagnostic manufacturers and specialized innovators drives technological progress and market dynamics. Manufacturers of molecular platforms have prioritized assay expansion, throughput enhancement, and connectivity features to meet the needs of diverse laboratory footprints. Simultaneously, companies focused on consumables and reagents emphasize quality control, lot-to-lot consistency, and logistical reliability to support uninterrupted testing programs. There is also a notable rise in specialized firms developing targeted assays for drug resistance markers and rapid susceptibility profiling, responding to clinical demand for faster therapeutic guidance.

Strategic partnerships between instrument providers and reagent suppliers have become more common, as they streamline procurement and service delivery for health systems. Innovators in digital radiography and artificial intelligence have pursued integrations with laboratory workflows to improve triage efficiency, while contract service providers and maintenance networks play an important role in sustaining equipment uptime, particularly in decentralized settings. Across the competitive landscape, companies that demonstrate robust regulatory compliance, dependable supply chains, and scalable training models tend to achieve wider clinical adoption. Looking ahead, collaboration between diagnostics developers, clinical researchers, and implementation partners will be essential to translate technical advances into routine clinical practice and public health impact.

Actionable strategic imperatives for diagnostics leaders to strengthen portfolios, supply chains, workforce capability, data integration, and stakeholder partnerships

Industry leaders should adopt a multi-pronged strategy that balances innovation, operational resilience, and stakeholder engagement. First, prioritize modular technology portfolios that allow rapid adaptation to changing clinical needs without requiring complete platform replacement. This approach reduces obsolescence risk and enables laboratories to scale specific assays as clinical demand evolves. Second, strengthen supply chain visibility by formalizing multi-supplier agreements, regional stocking strategies, and service-level commitments to reduce vulnerability to trade disruptions and component shortages.

Third, invest in workforce development and remote-support capabilities to ensure that technicians and clinicians can effectively use advanced diagnostics, interpret complex results, and maintain quality standards. Fourth, pursue interoperability and data integration initiatives that tie diagnostics into broader care pathways, enabling faster clinical action and improved surveillance. Fifth, engage proactively with regulatory bodies and payors to clarify reimbursement pathways and evidence requirements that support adoption. Finally, cultivate collaborative partnerships with public health programs and community providers to align diagnostic deployment with screening, contact tracing, and treatment-support strategies. Together, these steps will position organizations to respond nimbly to both clinical imperatives and operational challenges.

A transparent, multi-source research methodology integrating stakeholder interviews, clinical evidence, regulatory guidance, and supply chain assessments to validate insights

The research synthesized here draws on a structured and transparent methodology that integrates multiple evidence streams to support robust insight development. Primary inputs include stakeholder interviews with laboratory directors, clinicians, procurement officers, and manufacturer representatives, which provide first-hand perspectives on operational challenges and adoption drivers. These qualitative insights are complemented by systematic reviews of peer-reviewed clinical literature, technical guidance from authoritative public health agencies, and regulatory approvals that contextualize technology performance and intended use.

Additionally, the approach incorporates supply chain analysis and procurement practice reviews to assess sourcing vulnerabilities and logistical considerations. Comparative technology assessments evaluate assay performance characteristics, sample handling requirements, and implementation complexity to inform deployment scenarios. Throughout the research process, triangulation across data types ensured consistency of findings and highlighted areas of divergence for further exploration. Emphasis was placed on reproducibility of methods, explicit documentation of assumptions, and validation of insights with subject-matter experts to ensure practical relevance for decision-makers.

A succinct conclusion emphasizing the convergence of technology advances, operational resilience, and collaborative implementation to improve tuberculosis diagnostic outcomes

In synthesis, tuberculosis diagnostics are at an inflection point where technological advancements, regional implementation dynamics, and supply chain considerations converge to redefine diagnostic pathways. Molecular and nonmolecular technologies complement one another, enabling a layered approach to detection, triage, and resistance profiling that can improve clinical outcomes when integrated thoughtfully into care systems. At the same time, procurement strategies and operational practices must adapt to geopolitical developments and evolving demand patterns to preserve timely access to essential diagnostics.

Consequently, stakeholders who combine a strategic focus on adaptable technology portfolios, robust supply chain planning, workforce capacity-building, and regional implementation alignment will be best positioned to translate diagnostic innovation into sustained clinical and public health impact. Continued collaboration among manufacturers, health systems, and public health authorities will be critical to ensure that technological promise results in measurable improvements in diagnosis, treatment initiation, and containment of drug-resistant tuberculosis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Tuberculosis Diagnostics Market, by Product

  • 8.1. Consumables
    • 8.1.1. Kits
    • 8.1.2. Reagents
  • 8.2. Instruments

9. Tuberculosis Diagnostics Market, by Technology

  • 9.1. Molecular
    • 9.1.1. Genotypic Assays
    • 9.1.2. Nucleic Acid Amplification Tests
  • 9.2. Nonmolecular
    • 9.2.1. Imaging
    • 9.2.2. Immunological Assays

10. Tuberculosis Diagnostics Market, by Test Type

  • 10.1. Detection Test
    • 10.1.1. Blood Tests
    • 10.1.2. Culture-Based Tests
    • 10.1.3. Molecular Tests
    • 10.1.4. Skin Tests
    • 10.1.5. Smear Microscopy
  • 10.2. Drug Susceptibility Testing
    • 10.2.1. Molecular Dst
    • 10.2.2. Phenotypic Dst

11. Tuberculosis Diagnostics Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Reference Laboratories

12. Tuberculosis Diagnostics Market, by Application

  • 12.1. Active Tb
    • 12.1.1. Extrapulmonary Tb
    • 12.1.2. Pulmonary Tb
  • 12.2. Latent Tb

13. Tuberculosis Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Tuberculosis Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Tuberculosis Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Tuberculosis Diagnostics Market

17. China Tuberculosis Diagnostics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Molecular Inc.
  • 18.6. Becton, Dickinson and Company
  • 18.7. bioMerieux SA
  • 18.8. Cepheid, Inc.
  • 18.9. Hain Lifescience GmbH
  • 18.10. Hologic, Inc.
  • 18.11. Molbio Diagnostics Private Limited
  • 18.12. Oxford Immunotec
  • 18.13. QIAGEN N.V.
  • 18.14. Roche Diagnostics International AG
  • 18.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 201. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 203. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 204. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 206. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 207. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 209. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 210. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 237. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 239. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 240. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 242. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 243. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 245. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 246. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 249. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 251. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 252. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 254. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 255. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 257. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 258. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)